SCHEMBL229402

SCHEMBL229402

CC(C=O)Cc1cccc(C(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.46
TSHR P16473 1/20 0.46
TYR P14679 3/20 0.41
HDAC4 P56524 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MDM4 O15151 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
CA5A P35218 1/20 0.41
HTT P42858 1/20 0.41
MDM2 Q00987 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1654191 0.81 TP53 (0.49) TP53TSHRPNMTTAAR1MEN1
SCHEMBL9631362 0.80 TP53 (0.47) TP53TSHRALDH1A1MAPTTAAR1
SCHEMBL453825 0.79 TYR (0.44) TP53TSHRTYRHDAC4HDAC8
SCHEMBL11789845 0.79 HDAC4 (0.42) TP53TSHRTYRHDAC4HDAC8
SCHEMBL9600634 0.79 TP53 (0.46) TP53TSHRPNMTTAAR1
SCHEMBL27864550 0.79 PNMT (0.62) TP53TSHRCYP3A4MAPTPNMT
SCHEMBL28097748 0.77 PNMT (0.60) PNMTTAAR1HTR2AHTR2CHTR2B
SCHEMBL29487262 0.77 TSHR (0.61) TP53TSHRTYRALDH1A1MAPT
SCHEMBL1148 0.77 TSHR (0.61) TP53TSHRTYRALDH1A1MAPT
SCHEMBL97559 0.77 TP53 (0.60) TP53TSHRTDP1TAAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807241-B1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2022-04-13 EP claimed
US-9896650-B2 Encapsulates THE PROCTER & GAMBLE COMPANY (US) 2018-02-20 US claimed
US-20130017990-A1 LILIAL SURROGATE HENKEL AG & CO., KGAA (DE) 2013-01-17 US claimed
EP-2408885-A1 LILIAL SURROGATE Henkel AG & Co. KGaA (DE) 2012-01-25 EP claimed
US-20120004328-A1 LILIAN SURROGATE HENKEL AG & CO. KGAA (DE) 2012-01-05 US claimed
WO-2010105874-A1 LILIAL SURROGATE HENKEL AG & CO. KGAA (DE) 2010-09-23 WO claimed
WO-2010105873-A2 LILIAL SUBSTITUTE HENKEL AG & CO. KGAA (DE) 2010-09-23 WO claimed
US-6126930-A REDUCING TRIGEMINAL STIMULATION FROM AN ATOMIZED ALCOHOL THE PROCTER & GAMBLE COMPANY (US) 2000-10-03 US claimed
US-5843881-A Spray compositions THE PROCTER & GAMBLE COMPANY (US) 1998-12-01 US claimed
US-20260132388-A1 LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS NOVOZYMES A/S (DK) 2026-05-14 US disclosed
EP-4717756-A2 LIPASE VARIANTS AND DETERGENT COMPOSITIONS Novozymes A/S (DK) 2026-04-01 EP disclosed
US-12559736-B2 Lipase variants and polynucleotides encoding same NOVOZYMES A/S (DK) 2026-02-24 US disclosed
US-12545851-B2 Fragrances with note of lily of the valley SYMRISE AG (DE) 2026-02-10 US disclosed
US-12529017-B2 Detergent composition comprising a lipase NOVOZYMES A/S (DK) 2026-01-20 US disclosed
US-20070123441-A1 Stable odorant systems PROCTER & GAMBLE COMPANY, THE 2007-05-31 US disclosed
US-20070123440-A1 Stable odorant systems THE PROCTER & GAMBLE COMPANY 2007-05-31 US disclosed
US-6126930-A REDUCING TRIGEMINAL STIMULATION FROM AN ATOMIZED ALCOHOL THE PROCTER & GAMBLE COMPANY (US) 2000-10-03 US disclosed
EP-0986367-A1 SPRAY COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2000-03-22 EP disclosed
US-5843881-A Spray compositions THE PROCTER & GAMBLE COMPANY (US) 1998-12-01 US disclosed
WO-1998035651-A1 SPRAY COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1998-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559736-B2 Lipase variants and polynucleotides encoding same LPL, PNLIP, LIPG TP53 2207/4885TSHR 967/4885TYR 1719/4885
US-12545851-B2 Fragrances with note of lily of the valley TRPA1, CDY1; CDY1B, TMEM109 TP53 2498/4885TSHR 4528/4885TYR 93/4885
US-20260132388-A1 LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS LIPE, LPL, PNLIP TP53 1107/4885TSHR 1717/4885TYR 1462/4885
US-12529017-B2 Detergent composition comprising a lipase MGLL, LPL, LIPC TP53 2991/4885TSHR 1113/4885TYR 783/4885
US-20120004328-A1 LILIAN SURROGATE LOXL4, COXFA4L2, LOXL2 TP53 2033/4885TSHR 4490/4885TYR 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.